SLC6A3 and supranuclear palsy, progressive, 1: Using 123I-N-(3-iodopropen-2-yl)-2β-carbomethoxy-3β-(4-chlorophenyl) tropane (123I-IPT), Im et al. confirmed that PSP patients exhibit more pronounced but fairly uniform DAT loss in the striatal regions-of-interest versus PD.